KFF October 11, 2024
Elizabeth Williams, Alice Burns, Robin Rudowitz, Clea Bell

Managing the Medicaid prescription drug benefit and pharmacy expenditures is a long-standing policy priority for state Medicaid programs. Prescription drugs account for approximately 6% of total Medicaid spending, and Medicaid gross and net spending on prescription drugs continues to rise, in part due to the emergence of new, high cost drugs, including anti-obesity medications and cell and gene therapies that treat, and sometimes cure, rare diseases. Under the federal Medicaid Drug Rebate Program (MDRP), states must cover nearly all FDA-approved drugs from rebating manufacturers, but most states are in the process of implementing various cost containment initiatives to combat rising pharmacy costs such as value-based purchasing arrangements and pharmacy benefit manager (PBM) reforms. There have also been various federal actions...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Insurance, Medicaid, Pharma, Pharma / Biotech
CMS Moved to Expand Obesity Drug Coverage. Private Insurers Need to Step Up.
Redesigning Integrated Care For Dually Eligible People With Intellectual/Developmental Disabilities
Medicaid spending on weight loss, diabetes drugs up 500% since 2019: 5 numbers to know
CMS Launches New Program for Mental Health, OUD Treatment
Georgia Medicaid shakeup could force 3 in 4 beneficiaries to change plans: Centene CEO

Share This Article